Trevi Therapeutics (TRVI) Earnings Date & Reports

Key Takeaways

• Trevi Therapeutics (TRVI) is expected to report third-quarter 2026 results in mid-November, after the market close.
• Wall Street consensus points to a net loss of roughly $0.13 per share, with revenue expected to remain at $0.
• As a pre-revenue clinical-stage biotech, the report will center on cash runway and clinical development progress rather than sales.
• Trevi ended the second quarter of 2026 with approximately $319 million in cash, cash equivalents, and marketable securities, supporting an operating runway into 2030.
• Investors are watching closely for updates on the Haduvio chronic cough programs, with a key data readout anticipated in the fourth quarter of 2026.

Earnings Context and Why It Matters

Trevi Therapeutics is a clinical-stage biopharmaceutical company developing Haduvio, an oral extended-release form of nalbuphine, for chronic cough in patients with idiopathic pulmonary fibrosis (IPF), a progressive lung-scarring disease; chronic cough in patients with interstitial lung disease (ILD) not related to IPF; and refractory chronic cough (RCC). Because Trevi has not yet generated product revenue, its quarterly report serves less as a traditional earnings event and more as a checkpoint on financial runway and trial execution. With several late-stage studies underway, this update offers investors a timely signal on whether the company remains on track toward its planned data readouts and potential regulatory milestones.

Earnings Expectations

Analysts expect Trevi to report a net loss of approximately $0.13 per share for the third quarter of 2026, with individual estimates ranging from a loss of about $0.10 to $0.17 per share. Revenue is widely expected to remain at $0, consistent with the company's pre-commercial status. In the second quarter of 2026, Trevi posted a net loss of $0.11 per share, in line with consensus, while the first quarter of 2026 showed a loss of $0.09 per share that came in slightly below expectations.

For a company without revenue, the most important "metric" in the report is the cash balance. Trevi closed the second quarter of 2026 with about $319 million in cash, cash equivalents, and marketable securities, and management has reiterated cash runway guidance extending into 2030. Investors will be looking for confirmation that spending remains within budget as enrollment continues across its clinical programs.

AI Screener

Tickeron's AI Screener is an AI-powered stock and ETF (exchange-traded fund) discovery tool that helps traders and investors filter the market based on technical patterns, fundamentals, trends, volatility, and AI-driven signals. Users can scan thousands of stocks and ETFs using customizable filters such as industry, market capitalization, technical indicators, price patterns, and performance metrics. The screener is designed to help identify trade ideas, trending stocks, breakout candidates, and market opportunities more efficiently than manual screening. For investors tracking clinical-stage biotech names like Trevi Therapeutics alongside broader sector trends, the AI Screener offers a streamlined way to surface relevant opportunities.

Market Reaction and Investor Sentiment

Sentiment heading into the third-quarter report will likely hinge less on the headline loss and more on any commentary around clinical timelines and the company's competitive position in the chronic cough space. Trevi's shares have shown notable volatility around past earnings, with the stock historically experiencing meaningful post-announcement moves. The recent termination of a competing program in refractory chronic cough has increased investor focus on Trevi's data readout expected in the fourth quarter of 2026. Key risk factors include trial execution, enrollment pacing, and competition from other P2X3 antagonists and emerging chronic cough therapies.

Forward Outlook and Key Factors to Monitor

Following the earnings release, investors should focus on several forward-looking themes. First, any update on the timing and readiness of the anticipated data readout in the fourth quarter of 2026 will be central, as it represents a high-value inflection point for the chronic cough pipeline. Confirmation that the readout remains on schedule, or any shift in timing, is likely to drive sentiment.

Second, cash discipline matters. Trevi has emphasized that its current resources fund development through potential regulatory approval and extend runway into 2030. Investors will monitor research and development expense trends to gauge whether spending remains within the stated budget and whether the runway guidance is reaffirmed.

Third, competitive dynamics in chronic cough remain worth watching, including the progress of other P2X3 antagonists and related therapies. Finally, enrollment updates across the Phase 3 IPF program, the non-IPF ILD program, and the ongoing Phase 2b trial in refractory chronic cough will offer insight into operational momentum and future catalysts. As with any clinical-stage biotech, outcomes remain uncertain, and investors should weigh these developments alongside the company's execution record and broader biotech market conditions.

Disclaimer

The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.

Disclaimers and Limitations